Ozempic Cost in 2026

What Ozempic costs at NovoCare Pharmacy in 2026

Novo Nordisk sells Ozempic to cash-paying patients through its own pharmacy, NovoCare, and publishes the price. Patients new to the Ozempic Savings Offer or to NovoCare Pharmacy pay $199 for each month of 0.25 mg and 0.5 mg, covering two monthly fills through December 31, 2026. After that the price is $349 a month for 0.25 mg, 0.5 mg, or 1 mg, and $499 a month for 2 mg. The Ozempic pill starts at $149 a month and varies by dose. One month means one box containing one pen, or one bottle of 30 tablets.

The channel does not require a telehealth membership. Any licensed prescriber can send the prescription to NovoCare Pharmacy electronically, by fax, or by phone, and home delivery is free. Novo Nordisk states that it can modify or cancel the program at any time, which is the practical reason to check the price on the day you fill rather than trusting a figure quoted in an article, including this one.

Why the price step arrives before the highest dose does

The label sets the escalation, and the escalation sets when the price changes. Ozempic starts at 0.25 mg once weekly for four weeks, moves to 0.5 mg once weekly, then to 1 mg after at least four weeks, then to 2 mg after at least four more. Every one of those steps except the last sits at the same $349 self-pay price, so a patient who stops climbing at 1 mg holds a flat monthly cost. Reaching 2 mg raises the monthly price to $499, a 43% increase that has nothing to do with the pharmacy and everything to do with the dose on the prescription.

The pen strengths explain why the jump lands where it does. The 2 mg per 3 mL pen holds four doses of 0.25 mg, or two doses of 0.5 mg, or four doses of 0.5 mg; the 4 mg per 3 mL pen holds four doses of 1 mg; the 8 mg per 3 mL pen holds four doses of 2 mg. Each box is a month of weekly injections at one dose, so the price is quoted per box rather than per milligram. Where a clinician lands on that ladder is a clinical decision, and it is also the single largest lever on what a year of Ozempic costs.

The savings card: who reaches $25 and who is shut out

The Ozempic Savings Offer is a manufacturer copay program, not a discount on the cash price. With commercial insurance that covers Ozempic, the offer states a patient can pay as little as $25 a month, subject to a maximum saving of $100 a month. That cap is the part most summaries drop. If a plan leaves a $260 copay, the offer takes $100 off it and the patient pays $160, not $25. The $25 figure describes what happens when coverage is already strong.

Government beneficiaries are excluded, and the offer treats anyone holding both commercial and government-funded coverage as government insured. Amounts paid through the offer sit outside the insurance plan, so they do not count toward a deductible or an out-of-pocket maximum. For an uninsured patient the savings card is beside the point; the NovoCare self-pay price is the number that applies.

Why Medicare's GLP-1 Bridge skips Ozempic

The Medicare GLP-1 Bridge is a demonstration that gives eligible Part D beneficiaries a $50 monthly copay on certain GLP-1 drugs between July 1, 2026 and December 31, 2027. Ozempic is not one of them. Medicare lists the covered products as Foundayo tablets, Wegovy as injection or tablet, and the Zepbound KwikPen, and it frames eligibility around weight management: a BMI of 35 or higher, or 30 or higher with cardiovascular or kidney conditions, or 27 or higher with prediabetes or a prior cardiac event. Beneficiaries who have type 2 diabetes, moderate-to-severe sleep apnea, or fatty liver disease are excluded from the demonstration.

That exclusion catches the population Ozempic is labeled for. A Medicare beneficiary taking semaglutide for type 2 diabetes pays through the ordinary Part D benefit instead: a plan deductible capped at $615 in 2026, 25% coinsurance during the initial coverage stage, and catastrophic coverage once out-of-pocket spending on covered drugs reaches $2,100. The $2,100 ceiling is the number that matters most for a drug at this price, because it caps the year rather than the month. The $50 Bridge copay, by contrast, never counts toward that ceiling.

The negotiated Medicare price arriving January 1, 2027

CMS selected semaglutide for the second cycle of Medicare drug price negotiation, and the result covers Ozempic, Rybelsus, and Wegovy as one selected drug from Novo Nordisk. The negotiated maximum fair price for a 30-day supply in calendar year 2027 is $274, against a list price of $959 for a 30-day supply in 2024, a reduction of 71%. Those prices take effect on January 1, 2027.

The scale explains why this drug was selected first. CMS recorded $15,161,908,000 in Part D gross covered prescription drug costs for the semaglutide products in calendar year 2024, across the 2,282,000 Part D enrollees who used the drug that year. The negotiated price applies to Medicare, so it changes what Part D plans and their enrollees pay rather than the cash price at NovoCare. A self-pay patient outside Medicare should not expect the $274 figure to appear at the pharmacy counter in January.

What a telehealth Ozempic quote is actually buying

A telehealth program prescribing Ozempic supplies the same Novo Nordisk pen sold everywhere else, because there is one manufacturer and one product. What the program adds is the prescriber, the intake, the follow-up, and sometimes the pharmacy relationship. The drug price underneath is Novo's, so a program's quoted monthly figure is the pen plus a fee, whether or not the two are itemized. The catalog module above shows what programs currently publish for Ozempic, with the basis and the verification date attached to each row.

Three questions separate a reasonable quote from an expensive one. Ask whether the quoted price includes the medication or only the visit. Ask whether the clinician will send the prescription to NovoCare Pharmacy, since that is where the published self-pay price applies. Ask what happens to the price at the 2 mg dose, because the step from $349 to $499 belongs to the manufacturer and any program that hides it is quoting a number the patient will not keep paying.

Compounded semaglutide is not a cheaper Ozempic

Cheaper semaglutide advertised online is usually compounded, and FDA is direct about what that means: compounded drugs are not FDA approved, and the agency does not review them for safety, effectiveness, or quality before they are marketed. FDA has received 990 adverse-event reports associated with compounded semaglutide, a count it says is likely understated because state-licensed pharmacies are not required to report. Some products use semaglutide salts, and FDA states it lacks information on whether those salts share the chemical and pharmacologic properties of the active ingredient in the approved drug.

A compounded vial is therefore a different purchase, not a discount on this one, and it carries no Ozempic label, no Novo Nordisk pen, and no manufacturer price guarantee. Compounded products are widely sold for weight management, while Ozempic's label covers glycemic control in type 2 diabetes together with cardiovascular and kidney risk reduction. Readers comparing the two on price alone are comparing an approved product against an unapproved one, and FDA's guidance is to fill any prescription at a state-licensed pharmacy.

Compounded semaglutide is not an FDA-approved product and is not an equivalent, generic, or substitute for Ozempic. Any switch between products is a clinical decision.